N-acetylcysteine in Bulimia Nervosa

Phase 3TerminatedNCT01131572

Lindner Center of HOPE11 enrolled

Overview

This study tests NAC in the treatment of Bulimia Nervosa.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

NAC

Interventions

N-acetylcysteine NACDRUG

N-acetylcysteine in the treatment of Bulimia Nervosa

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Bulimia Nervosa * 18-65 years of age

Locations (1)

Lindner Center of HOPE

Mason, Ohio, United States

Outcomes

Primary Outcomes

Binge-purge episodes

The primary outcome measure will be the weekly frequency of binge-purge episodes. A binge-purge eating episode will be defined using DSM-IV-TR criteria, and accessed via clinical interview and review of subject take-home diaries at each study visit.

Time frame: per week

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.